Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rowe

Showing results (461-470 of 632) with videos related to

Pageof 64
Sort By:
Clinical Nuclear Medicine|April 19, 2022
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and TherapySebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2019
Prospective Evaluation of PSMA-Targeted <sup>18</sup>F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate CancerSteven P Rowe, Scott P Campbell, Margarita Mana-Ay, et al.
European Urology|April 12, 2021
A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate CancerMohammad S Sadaghiani, Sara Sheikhbahaei, Rudolf A Werner, et al.
Tomography (Ann Arbor, Mich.)|August 25, 2023
Detection of Biochemically Recurrent Prostate Cancer with [<sup>18</sup>F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen ParametersMohammad S Sadaghiani, Sara Sheikhbahaei, Abdullah Al-Zaghal, et al.
Science (New York, N.Y.)|June 14, 1985
Free radicals in the stratosphere: a new observational techniqueJ G Anderson, N L Hazen, B E McLaren, et al.
The Journal of Urology|April 7, 2020
Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on <sup>18</sup>F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate CancerMark C Markowski, Ramy Sedhom, Wei Fu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2025
Safety, Dosimetry, and Feasibility of [<sup>68</sup>Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate CancerLiza Lindenberg, Thomas A Hope, Frank I Lin, et al.
Theranostics|January 8, 2019
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?Rudolf A Werner, Alexander Weich, Malte Kircher, et al.
Medical Oncology (Northwood, London, England)|June 12, 2020
Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancerD K Reyes, S P Rowe, E M Schaeffer, et al.
Hearing Research|November 2, 2017
Cannula-based drug delivery to the guinea pig round window causes a lasting hearing loss that may be temporarily mitigated by BDNFPhillip J P Sale, Aaron Uschakov, Tasfia Saief, et al.
Pageof 64

Showing results (461-470 of 632) with videos related to

Sort By:
Pageof 64
Clinical Nuclear Medicine|April 19, 2022
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and TherapySebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2019
Prospective Evaluation of PSMA-Targeted <sup>18</sup>F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate CancerSteven P Rowe, Scott P Campbell, Margarita Mana-Ay, et al.
European Urology|April 12, 2021
A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate CancerMohammad S Sadaghiani, Sara Sheikhbahaei, Rudolf A Werner, et al.
Tomography (Ann Arbor, Mich.)|August 25, 2023
Detection of Biochemically Recurrent Prostate Cancer with [<sup>18</sup>F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen ParametersMohammad S Sadaghiani, Sara Sheikhbahaei, Abdullah Al-Zaghal, et al.
Science (New York, N.Y.)|June 14, 1985
Free radicals in the stratosphere: a new observational techniqueJ G Anderson, N L Hazen, B E McLaren, et al.
The Journal of Urology|April 7, 2020
Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on <sup>18</sup>F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate CancerMark C Markowski, Ramy Sedhom, Wei Fu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2025
Safety, Dosimetry, and Feasibility of [<sup>68</sup>Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate CancerLiza Lindenberg, Thomas A Hope, Frank I Lin, et al.
Theranostics|January 8, 2019
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?Rudolf A Werner, Alexander Weich, Malte Kircher, et al.
Medical Oncology (Northwood, London, England)|June 12, 2020
Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancerD K Reyes, S P Rowe, E M Schaeffer, et al.
Hearing Research|November 2, 2017
Cannula-based drug delivery to the guinea pig round window causes a lasting hearing loss that may be temporarily mitigated by BDNFPhillip J P Sale, Aaron Uschakov, Tasfia Saief, et al.
Pageof 64